DOI: https://dx.doi.org/10.18203/issn.2454-2156.IntJSciRep20220752
Published: 2022-03-23

Neuromyelitis optica spectrum: a case report

Harshini Kancherla, Maheswari S. Kadimella, Ramya Bala Prabha Gelly, Ramo R. Tadikonda

Abstract


Neuromyelitis optica (NMO) or Devic's disease is a rare inflammatory, demyelinating autoimmune disease of the central nervous system that primarily affects women, most commonly in their 30s and 40s. NMOSD has been linked to several different illnesses including autoimmune disorders. Recurrent bouts of optic neuritis, myelitis and brainstem disorders are caused by serum antibodies (Abs) against the aquaporin-4 (AQP4) water channel. No AQP4-Abs are detected in some patients with NMOSD symptoms, but Abs against myelin-oligodendrocyte-glycoprotein (MOG). The term MOG-encephalomyelitis is now commonly used to describe this clinical disorder. Long segments of inflammation in the spinal cord (myelitis), severe optic neuritis and bouts of persistent vomiting and hiccoughs are all characteristics symptoms. This was the case of 30 year old female who presented with a chief complaint of weakness of both lower limbs, unable to walk, tingling and numbness. Based on her MRI findings revealed that the patient was diagnosed with NMO spectrum. She was treated with immunosuppressants and corticosteroids.


Keywords


Aquaporin-4, Demyelinating, Devic’s disease, Neuromyelitis optic spectrum

Full Text:

PDF

References


Beiruti K, Saleh SA, Daitzchman M, Shahien R. Neuromyelitis optica spectrum disorder: a case report. J Mult Scler. 2016;3(20):192.

Neuromyelitis Optica Spectrum Disorder (NMOSD) @2018 The Transverse Myelitis Association.

Fujiwara S, Manabe Y, Monihara R, Yunoki T, Kono S, Narai H, et al. Two cases of very late-onset neuromyelitis optica spectrum (NMOSD) in patients over the age of 80. Case Rep Neurol. 2020;12(1):13-7.

Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis Optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501.

Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optics spectrum disorder. Clin Med (Lond). 2019;19(2)):169-76.

Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:888.

Fujihara K. Neuromyelitis optica spectrum disorder still evolving & broadening. Curr Opin Neurol. 2019;32(3):385-94.

Koon-Ho C, Chi-Yan L. Treatment of neuromyelitis optica spectrum disorders. Int J Mol Sci. 2021;22(16);8638.

Contentti EC, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflamm. 2021;18(1):208.

Rosenthal JF, Hoffman BM, Tyor WR. CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. J Investig Med. 2020;68(2):321-30.

Gurgen N, Yalcin D, Gozukizl ST, Polisci D. Neuromyelitis optica: case report. Olgu Sunumlari. 2016;50(2):166-70.

Tambunam L, Ritarwan K, Surbakti KP. Neuromyelitis optica spectrum disorder: a case report of effective combination immunosuppressant, corticosteroids, and therapeutic plasma exchange. J Med Sci. 2019;7(20):3433-6.

Bradshaw, MD, Kimbrough D. Neuromyelitis optic spectrum disorders. Pract Neurol. 2019.